# Clerkenwell Health

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/clerkenwell-health

- Industry: Healthcare
- Headquarters: London, UK
- Website: www.clerkenwellhealth.com
- Total disclosed funding: $2.6M
- Latest round: Seed (Jun 23, 2022)
- Investors on record: 3

## About

Based in London, UK, and founded in 2020, Clerkenwell Clinics Limited, doing business as Clerkenwell Health, operates as a mental health company that provides psychedelic-specialist CRO (contract research organization) services such as psychedelic-drug clinical trials, and trial management for its clients. The company was co-founded by Thomas Mcdonald (CEO), Sam Lewis (CFO), and Henry Fisher (CSO), and in October 2022, Clerkenwell Health raised GBP 2.1 million in seed funding from Convergence Partners and Exceptional Ventures, with participation from Lionheart Ventures.

The firm offers a wide range of bespoke services including clinical trial design, scientific and regulatory advisory, clinical trial delivery (through a state-of-the-art facility), trial monitoring and management, etc., primarily for psychedelic drug manufacturers to help them accelerate the drug development process ranging from phase I to III trials to FDA approval and market launch. The company also conducts clinical trials for any conditions that the clients are interested in studying. Clerkenwell Clinics Limited’s in-house team comprises clinical trial managers, scientists, psychiatric, and psychedelic specialists, etc.

The company intends to use the October 2022 funding to make its London facility fully operational.

## Funding rounds

- Seed, Jun 23, 2022, $2.6M — Solcon Capital, Lionheart Ventures, Exceptional Ventures

## Investors

- Solcon Capital (https://capitalatlas.ai/funds/solcon-capital) — Seed
- Lionheart Ventures (https://capitalatlas.ai/funds/lionheart-ventures) — Seed
- Exceptional Ventures (https://capitalatlas.ai/funds/exceptional-ventures) — Seed